IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

NCT05805956 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Advanced Lung Cancer
Advanced Gastric Carcinoma
Advanced Cholangiocarcinoma

Interventions

DRUG: IMM2902

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.